IDEAYA Biosciences (IDYA) Competitors $22.48 -0.32 (-1.40%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$22.46 -0.02 (-0.09%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDYA vs. ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, TLX, and AXSMShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. IDEAYA Biosciences vs. Its Competitors Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Telix Pharmaceuticals Axsome Therapeutics IDEAYA Biosciences (NASDAQ:IDYA) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Does the media prefer IDYA or ROIV? In the previous week, IDEAYA Biosciences had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.18 beat IDEAYA Biosciences' score of 0.87 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IDYA or ROIV? IDEAYA Biosciences presently has a consensus target price of $47.55, suggesting a potential upside of 111.50%. Roivant Sciences has a consensus target price of $16.50, suggesting a potential upside of 45.25%. Given IDEAYA Biosciences' higher possible upside, equities analysts clearly believe IDEAYA Biosciences is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.85Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more volatility and risk, IDYA or ROIV? IDEAYA Biosciences has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Is IDYA or ROIV more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -225.71%. Roivant Sciences' return on equity of -14.76% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -29.28% -27.68% Roivant Sciences -225.71%-14.76%-13.69% Do institutionals and insiders hold more shares of IDYA or ROIV? 98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 2.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, IDYA or ROIV? Roivant Sciences has higher revenue and earnings than IDEAYA Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M281.26-$274.48M-$3.59-6.26Roivant Sciences$29.05M265.84-$171.98M-$0.25-45.44 SummaryRoivant Sciences beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.00B$2.97B$5.62B$9.09BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-6.2620.7128.1320.27Price / Sales281.26288.27428.2698.57Price / CashN/A42.8637.4658.16Price / Book1.847.638.045.49Net Income-$274.48M-$55.05M$3.18B$250.45M7 Day Performance1.77%8.43%3.62%4.79%1 Month Performance0.90%5.42%4.06%7.68%1 Year Performance-43.80%2.03%30.01%16.43% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences3.6232 of 5 stars$22.48-1.4%$47.55+111.5%-43.3%$2.00B$7M-6.2680News CoverageAnalyst UpgradeROIVRoivant Sciences2.8383 of 5 stars$10.74-2.3%$17.50+62.9%+1.1%$7.47B$29.05M0.00860Analyst UpgradeELANElanco Animal Health1.5099 of 5 stars$14.48-1.1%$15.33+5.9%+9.0%$7.27B$4.44B15.579,000News CoverageRVMDRevolution Medicines4.5768 of 5 stars$36.67-3.2%$67.58+84.3%-12.3%$7.05B$11.58M0.00250LEGNLegend Biotech3.3981 of 5 stars$35.87+0.6%$72.60+102.4%-19.7%$6.55B$627.24M0.002,609Analyst ForecastGRFSGrifols3.9722 of 5 stars$8.87-2.3%$10.30+16.1%+10.1%$6.24B$7.81B7.5823,822News CoverageTGTXTG Therapeutics3.7943 of 5 stars$35.98-2.0%$40.80+13.4%+73.4%$5.83B$329M149.92290News CoveragePositive NewsAnalyst UpgradeNUVLNuvalent3.3079 of 5 stars$77.93-3.2%$119.60+53.5%+3.8%$5.78BN/A0.0040Insider TradeLNTHLantheus4.5774 of 5 stars$79.19-1.5%$130.50+64.8%-34.2%$5.56B$1.53B14.03700News CoveragePositive NewsTLXTelix PharmaceuticalsN/A$15.48-3.7%$22.33+44.3%N/A$5.44B$516.72M0.00N/ANews CoverageAnalyst ForecastAXSMAxsome Therapeutics4.7404 of 5 stars$107.50+2.0%$172.33+60.3%+28.9%$5.19B$385.69M0.00380Analyst Revision Related Companies and Tools Related Companies Roivant Sciences Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDYA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredDid you miss out on Trump’s “birthday gift” to Americans?While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts